New Dermal Filler for Lip Augmentation
Launched by GALDERMA R&D · Oct 20, 2017
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects willing to comply with the requirements of the study and providing a signed written informed consent.
- • Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
- • Seeking augmentation therapy for the lips
- Exclusion Criteria:
- • Allergy of hypersensitivity to any injectable hyaluronic acid gel or to gram positive bacterial proteins.
- • Allergy or hypersensitivity to lidocaine or other amide-type anesthetics, or topical anesthetics or nerve blocking agents.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Chestnut Hill, Massachusetts, United States
Alpharetta, Georgia, United States
New York, New York, United States
Solana Beach, California, United States
Birmingham, Michigan, United States
San Diego, California, United States
Nashville, Tennessee, United States
Encino, California, United States
Coral Gables, Florida, United States
West Palm Beach, Florida, United States
Hunt Valley, Maryland, United States
Chapel Hill, North Carolina, United States
Dallas, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials